CYTOKINETICS INC — Director's Dealing 2020

Mar 9, 2020

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: CYTOKINETICS INC (CYTK)
CIK: 0001061983
Period of Report: 2020-03-06

Reporting Person: Malik Fady Ibraham (EVP Research & Development)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2020-03-06	Common Stock	A	50000	$0.0	Acquired	156621	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2020-03-06	Incentive Stock Option (right to buy)	$14.4	A	10854	Acquired	2030-03-05	Common Stock (10854)	Direct
2020-03-06	Non-Qualified Stock Option (right to buy)	$14.4	A	79146	Acquired	2030-03-05	Common Stock (79146)	Direct

Footnotes

F1: Includes up to 5,135 shares of common stock purchased pursuant to the Cytokinetics, Incorporated Employee Stock Purchase Plan.

F2: This option shall vest and become exercisable over 4 years, with shares divided into equal monthly installments, such that the option shall be 100% vested four years from the date of grant.